{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:28:46Z","timestamp":1789032526990,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.lungcan.2025.108616","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T11:17:31Z","timestamp":1748949451000},"page":"108616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Survival and prognostic factors of HER2-mutant advanced non-small cell lung cancer with brain metastases"],"prefix":"10.1016","volume":"205","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9217-8343","authenticated-orcid":false,"given":"Qian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2828-8774","authenticated-orcid":false,"given":"Mingying","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5891-4978","authenticated-orcid":false,"given":"Zichao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haicheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanchen","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shichao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1755-0175","authenticated-orcid":false,"given":"Yun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.lungcan.2025.108616_b0005","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/annonc\/mdv573","article-title":"Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort","volume":"27","author":"Mazi\u00e8res","year":"2016","journal-title":"Ann. Oncol."},{"issue":"16","key":"10.1016\/j.lungcan.2025.108616_b0010","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.2012.45.6095","article-title":"Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives","volume":"31","author":"Mazi\u00e8res","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.lungcan.2025.108616_b0015","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1158\/1078-0432.CCR-12-0912","article-title":"Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas","volume":"18","author":"Arcila","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"24","key":"10.1016\/j.lungcan.2025.108616_b0020","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1002\/cncr.32461","article-title":"Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers","volume":"125","author":"Offin","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2025.108616_b0025","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221082339","article-title":"First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2-altered NSCLC: a retrospective real-world POLISH study","volume":"14","author":"Yang","year":"2022","journal-title":"Ther Adv Med Oncol"},{"issue":"7","key":"10.1016\/j.lungcan.2025.108616_b0030","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1093\/annonc\/mdv186","article-title":"Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors","volume":"26","author":"Kris","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2025.108616_b0035","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejca.2018.11.030","article-title":"Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study","volume":"109","author":"Lai","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2025.108616_b0040","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1634\/theoncologist.2019-0547","article-title":"Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma","volume":"25","author":"Fang","year":"2020","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.lungcan.2025.108616_b0045","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.21.01323","article-title":"Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations after prior Therapies: ZENITH20-2 Trial","volume":"40","author":"Le","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.lungcan.2025.108616_b0050","first-page":"2753","article-title":"Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma after Platinum-based Chemotherapy: a Multicenter","volume":"38","author":"Zhou","year":"2020","journal-title":"Open-Label, Single-Arm, Phase II Study, J Clin Oncol"},{"issue":"8","key":"10.1016\/j.lungcan.2025.108616_b0055","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1038\/s41591-023-02461-x","article-title":"First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial","volume":"29","author":"Liu","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.lungcan.2025.108616_b0060","article-title":"MA12.09 Zongertinib (BI 1810631) for HER2-positive Solid Tumors with Brain Metastases:Subanalysis of the Beamion LUNG-1 Trial","author":"Opdam","year":"2024","journal-title":"WCLC"},{"key":"10.1016\/j.lungcan.2025.108616_b0065","article-title":"PL04.04 Primary phase Ib Analysis of Beamion LUNG-1: Zongertinib (BI 1810631) in patients with HER2 Mutation-positive NSCLC","author":"Ruiter","year":"2024","journal-title":"WCLC"},{"key":"10.1016\/j.lungcan.2025.108616_b0070","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1556-0864(25)00198-4","article-title":"3O - phase I\/II SOHO-01 study of BAY 2927088 in patients with previously treated HER2-mutant NSCLC: Safety and efficacy results from 2 expansion cohorts","volume":"20","author":"Girard","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108616_b0075","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer","volume":"386","author":"Li","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108616_b0080","doi-asserted-by":"crossref","first-page":"S762","DOI":"10.1016\/j.annonc.2023.09.2354","article-title":"1321MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non\u2013small cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02","volume":"34","author":"Li","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2025.108616_b0085","unstructured":"International Comprehensive Cancer Network. Version 3.2025 Non-Small Cell Lung Cancer. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108616_b0090","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/s12885-018-4277-x","article-title":"Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers","volume":"18","author":"Wang","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lungcan.2025.108616_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107315","article-title":"Exploration on the first-line treatment of ERBB2-altered advanced non-small cell lung cancer: a multicenter retrospective study","volume":"183","author":"Chen","year":"2023","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108616_b0100","doi-asserted-by":"crossref","first-page":"488","DOI":"10.4143\/crt.2022.359","article-title":"Real World Characteristics and Clinical Outcomes of HER2-Mutant Non-Small Cell Lung Cancer patients Detected by Next-Generation Sequencing","volume":"55","author":"Ahn","year":"2023","journal-title":"Cancer Res. Treat."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108616_b0105","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.2011.38.0527","article-title":"Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases","volume":"30","author":"Sperduto","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108616_b0110","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-Update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2025.108616_b0115","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response assessment criteria for brain metastases: proposal from the RANO group","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2025.108616_b0120","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.jtho.2023.06.017","article-title":"Genomic Alterations and the Incidence of Brain Metastases in Advanced and Metastatic NSCLC: a Systematic Review and Meta-Analysis","volume":"18","author":"Gillespie","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108616_b0125","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2025.108616_b0130","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s10147-014-0760-9","article-title":"Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations","volume":"20","author":"Iuchi","year":"2015","journal-title":"Int. J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.lungcan.2025.108616_b0135","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1002\/cncr.27409","article-title":"Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer","volume":"118","author":"Doebele","year":"2012","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108616_b0140","doi-asserted-by":"crossref","first-page":"753","DOI":"10.21037\/tlcr-20-559","article-title":"Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations","volume":"10","author":"Yang","year":"2021","journal-title":"Transl Lung Cancer Res"},{"issue":"16_suppl","key":"10.1016\/j.lungcan.2025.108616_b0145","doi-asserted-by":"crossref","first-page":"8546","DOI":"10.1200\/JCO.2022.40.16_suppl.8546","article-title":"Molecular characteristics of ERBB2-activating mutations in chinese patients with NSCLC","volume":"40","author":"Xu","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"31","key":"10.1016\/j.lungcan.2025.108616_b0150","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab Deruxtecan in patients with HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary results from the Randomized, phase II DESTINY-Lung02 Trial","volume":"41","author":"Goto","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2025.108616_b0155","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16101902","article-title":"An Anti-VEGF-B Antibody Reduces Abnormal Tumor Vasculature and Enhances the Effects of Chemotherapy","volume":"16","author":"Janes","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.lungcan.2025.108616_b0160","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002891","article-title":"Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer","volume":"9","author":"Negrao","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"8","key":"10.1016\/j.lungcan.2025.108616_b0165","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/s41556-019-0352-z","article-title":"HER2 recruits AKT1 to disrupt STING signalling and suppress antiviral defence and antitumour immunity","volume":"21","author":"Wu","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.lungcan.2025.108616_b0170","article-title":"PL04.03 Safety and efficacy of BAY 2927088 in patients with HER2-mutant NSCLC: expansion cohort from the phase I\/II SOHO-01 study","author":"Le","year":"2024","journal-title":"WCLC"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108616_b0175","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41392-024-01897-y","article-title":"SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1\/2 study","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108616_b0180","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.trecan.2023.01.003","article-title":"Antibody-drug conjugates: in search of partners of choice","volume":"9","author":"Fuentes-Antr\u00e1s","year":"2023","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108616_b0185","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jtho.2021.08.009","article-title":"Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination with Radiation","volume":"17","author":"Thomas","year":"2022","journal-title":"J. Thorac. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225005082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225005082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T14:49:33Z","timestamp":1752590973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225005082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":37,"alternative-id":["S0169500225005082"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108616","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival and prognostic factors of HER2-mutant advanced non-small cell lung cancer with brain metastases","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108616","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108616"}}